<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312671</article-id>
      <article-id pub-id-type="pmc">4540505</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153692</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Combined acute interstitial pneumonitis and pancytopenia induced by
low-dose methotrexate in a hemodialysis patient treated for bullous pemphigoid<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Haibo</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Fang</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Min</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yan</surname>
            <given-names>Wenliang</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sang</surname>
            <given-names>Hong</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <aff id="aff01"><label>1</label>Nanjing University - Nanjing, China.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Hong Sang, 305 East Zhongshan Road, Nanjing, 210002,
China. <bold>E-mail:</bold><email>shzwqzsl@163.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>43</fpage>
      <lpage>45</lpage>
      <history>
        <date date-type="received">
          <day>10</day>
          <month>5</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>6</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Methotrexate has been widely used for many years in the treatment of a variety of
diseases. Acute pneumonitis and bone marrow suppression are very serious side effects
in methotrexate treatment. A 48-year-old man with end-stage renal disease undergoing
chronic hemodialysis developed combined acute pneumonitis and pancytopenia after a
cumulative dose of 20 mg methotrexate for bullous pemphigoid. Continuous renal
replacement therapy (CRRT) can effi ciently decrease serum methotrexate
concentration. A rapid improvement of clinical symptoms and resolution of pulmonary
opacifi cation were found after CRRT. Blood cell counts returned to normal after
component blood transfusion and cytokine supportive therapy. Patients with impaired
renal function are at high risk of methotrexate toxicity, and low-dose methotrexate
should be prescribed with great caution.</p>
      </abstract>
      <kwd-group>
        <kwd>Methotrexate</kwd>
        <kwd>Pancytopenia</kwd>
        <kwd>Pneumonia</kwd>
        <kwd>Renal dialysis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Methotrexate (MTX) is always taken on a once-weekly basis, with smaller doses for skin
problems. Along with its needed effects, MTX has several potential side effects,
including acute pneumonitis and bone marrow suppression, which are very serious and
sometimes life-threatening. The background dermatological diseases of MTX pneumonitis
reported to date include psoriasis, mycosis fungoides, and pemphigus vulgaris.<sup><xref rid="r01" ref-type="bibr">1</xref></sup> No MTX pneumonitis has been found in
patients with bullous pemphigoid, and only one case of fatal pancytopenia has been
reported in a hemodialysis patient with bullous pemphigoid.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Here we report a case of combined acute intersitial
pneumonitis and pancytopenia induced by low-dose MTX in a hemodialysis patient treated
for bullous pemphigoid.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A 48-year-old man was treated with hemodialysis (three times/week) in 2008 for end-stage
renal disease due to chronic glomerulonephritis. On 26<sup>th</sup> June 2013, the
patient was hospitalized because of bullous pemphigoid, which was diagnosed on clinical,
histopathological, and immunofluorescence grounds (<xref ref-type="fig" rid="f01">Figure
1A</xref>). Histopathological examination showed subepidermal blister formation and
direct immunofluorescence revealed a linear deposit of IgG and C3 (data not shown) along
the basement membrane (<xref ref-type="fig" rid="f01">Figures 1B</xref> and <xref ref-type="fig" rid="f01">1C</xref>). Application of methylprednisolone (60 mg daily)
and topical halometasone failed to control the disease. A heterozygous (CT),
methylenetetrahydrofolate reductase (MTHFR) genotype was confirmed by PCR. Oral MTX (10
mg weekly) was then given and folic acid was prescribed. MTX addition led to rapid
symptomatic improvement and cessation of new bullae formation. On the fifth day, after
the second MTX dose, the patient complained of acute shortness of breath, non-productive
cough, and fever. Physical examination revealed inspiratory rales over both lower lung
fields. Arterial blood gas analysis revealed a PaO2 of 49 mm Hg, PaCO<sub>2</sub> of 30
mm Hg, and pH of 7.42 on room air. A high-resolution CT scan showed extensive
ground-glass infiltrates in both lungs (<xref ref-type="fig" rid="f02">Figure
2A</xref>). The patient satisfied criteria for MTX pneumonitis according to the
aforementioned findings and other supportive evidences.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> MTX was stopped,
methylprednisolone was maintained at 60 mg daily, and the patient was treated with nasal
oxygen. The hemodialysis was then carried out once daily to eliminate MTX. Serum MTX
level was measured by using the Syva enzyme multiplied immunoassay technique (EMIT).
After five hemodialysis procedures, the serum MTX level was still 0.14 &#xB5;mol/L, the same
as after the first hemodialysis. No apparent improvement in pulmonary infiltrates was
found, as evidenced by repeat CT scan. The patient was transferred to the Urology
Department to receive continuous renal replacement therapy (CRRT). After one day of CRRT
using continuous veno-venous haemofiltration (CVVH), the patient rapidly improved and
serum MTX level decreased from 0.14 (72-hour MTX concentration &gt;0.1 &#xB5;mol/L is
considered as at risk of toxicity) to 0.07 &#xB5;mol/L. Pulmonary interstitial infiltrates
gradually resolved and a nearly complete resolution of pulmonar infiltrates was found 3
days after CRRT initiation. Arterial blood gas analysis was also found to be normal
(<xref ref-type="fig" rid="f02">Figures 2B</xref> and <xref ref-type="fig" rid="f02">2C</xref>). On the sixth day, after the second MTX dose, blood analysis confirmed
pancytopenia: WBC count was 1.8 ' 10<sup>9</sup>/L, hemoglobin concentration was 51 g/L,
and platelet count was 49 ' 10<sup>9</sup>/L. His pancytopenia recovered after component
blood transfusion and cytokine supportive treatment (G-CSF and IL-11).
Methylprednisolone was converted to prednisone to control skin lesions after recovery
from pneumonitis. The patient did not complain of respiratory symptoms during a 3-month
follow-up.</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p><bold>A.</bold> Blisters on the trunk of the patient&#x2019;s body. <bold>B.</bold>
Histopathological examination shows subepidermal blister formation and
perivascular infi ltrates in the dermis. <bold>C.</bold> Direct immunofluorescence
reveals a linear deposit of IgG along the basement membrane</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0043-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p><bold>A.</bold>CT scan shows extensive ground-glass infi ltrates in both lungs.
<bold>B</bold> and <bold>C.</bold> The resolution of pulmonary opacifi cation
during <bold>(B)</bold> and after <bold>(C)</bold> CRRT therapy</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0043-g02"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>MTX is not recommended in case of a creatinine clearance &lt; 10 mL/mn<sup>2</sup>. A
study has suggested that MTX, which is highly bound to albumin, can be removed by
hemodialysis. <sup><xref rid="r04" ref-type="bibr">4</xref></sup> This finding makes MTX
a viable treatment option in uremic patients. Recently, Vilay <italic>et al</italic>
have demonstrated successful treatment of MTX intoxication by using continuous
extracorporeal therapy and glucarpidase in a patient with osteosarcoma. <sup><xref rid="r05" ref-type="bibr">5</xref></sup> Of particular importance is the use of
continuous veno-venous hemodialysis (CVVHD) and continuous veno-venous hemodiafiltration
(CVVHDF). CVVHD and CVVHDF are different CRRT modes and either one of them can
efficiently increase MTX removal. This view is also supported in our patient, who
received CRRT therapy using CVVH.</p>
      <p>Another report has stated MTX is poorly removed by hemodialysis, although removal
through hemodialysis is greater than through peritoneal dialysis. <sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup>
The authors believe that MTX, even in low dose, should not be prescribed to dialysis
patients. <sup><xref rid="r06" ref-type="bibr">6</xref></sup> Our findings also
suggested poor removal of MTX by hemodialysis, since five hemodialysis procedures failed
to reduce serum MTX. The failure to eliminate MTX may be associated with the absence of
high-flux membrane in hemodialysis, as high-flux hemodialysis has been proven to
efficiently reduce serum MTX level, despite the failed clearance of polyglutamated MTX
metabolite within cells. <sup><xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>The risk factors that have been suggested for MTX pneumonitis include preexisting
pulmonary disease or abnormalities on chest radiographs, smoking, acetylsalicylic acid
use, and renal insufficiency. <sup><xref rid="r08" ref-type="bibr">8</xref></sup> Risk
factors for pancytopenia include impaired renal function, hypoalbuminemia, advanced age,
concurrent infection, and/or concurrent medication. <sup><xref rid="r09" ref-type="bibr">9</xref></sup> As to our patient, impaired renal function may be the most
important risk factor both for MTX pneumonitis and pancytopenia. It is uncertain whether
the heterozygous <italic>MTHFR</italic> genotype in our patient is associated with MTX
toxicity, because CC and CT genotypes showed no significant differences in risk of MTX
toxicity. <sup><xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Low-dose MTX must be prescribed with great caution to uremic patients. Alternative
medicines (azathioprine or mycophenolate mofetil) should be considered.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Liu H, Liu F, Zhang M, Yan W, Sang H. Combined
acute interstitial pneumonitis and pancytopenia induced by low-dose methotrexate in a
hemodialysis patient treated for bullous pemphigoid. An Bras Dermatol. 2015;90 (3
Suppl 1): S43-5.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Study conducted at the Department of Dermatology, Jinling Hospital, affi liated to
the Nanjing University, School of Medicine - Nanjing, China.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Imokawa</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Colby</surname>
              <given-names>TV</given-names>
            </name>
            <name>
              <surname>Leslie</surname>
              <given-names>KO</given-names>
            </name>
            <name>
              <surname>Helmers</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate pneumonitis: review of the literature and
histopathological findings in nine patients</article-title>
          <source>Eur Respir J</source>
          <year>2000</year>
          <volume>15</volume>
          <fpage>373</fpage>
          <lpage>381</lpage>
          <pub-id pub-id-type="pmid">10706507</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Seneschal</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>H&#xE9;liot-Hostein</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Taieb</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Pancytopenia induced by low-dose methotrexate in a haemodialysis
patient treated for bullous pemphigoid</article-title>
          <source>J Eur Acad Dermatol Venereol</source>
          <year>2007</year>
          <volume>21</volume>
          <fpage>1135</fpage>
          <lpage>1136</lpage>
          <pub-id pub-id-type="pmid">17714155</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Searles</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>McKendry</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate pneumonitis in rheumatoid arthritis: potential risk
factors. Four case reports and a review of the literature</article-title>
          <source>J Rheumatol</source>
          <year>1987</year>
          <volume>14</volume>
          <fpage>1164</fpage>
          <lpage>1171</lpage>
          <pub-id pub-id-type="pmid">3325643</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diskin</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Stokes</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Dansby</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>Radcliff</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>TB</given-names>
            </name>
          </person-group>
          <article-title>Removal of methotrexate by peritoneal dialysis and hemodialysis in a
single patient with end-stage renal disease</article-title>
          <source>Am J Med Sci</source>
          <year>2006</year>
          <volume>332</volume>
          <fpage>156</fpage>
          <lpage>158</lpage>
          <pub-id pub-id-type="pmid">16969149</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vilay</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Mueller</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Haines</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Alten</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Askenazi</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Treatment of methotrexate intoxication with various modalities of
continuous extracorporeal therapy and glucarpidase</article-title>
          <source>Pharmacotherapy</source>
          <year>2010</year>
          <volume>30</volume>
          <fpage>111</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="pmid">20030480</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Basile</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Montanaro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Semeraro</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Should low-dose methotrexate therapy be prescribed to dialysis
patients</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2002</year>
          <volume>17</volume>
          <fpage>530</fpage>
          <lpage>531</lpage>
          <pub-id pub-id-type="pmid">11865117</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wall</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Johansen</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Molony</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>DuBose</surname>
              <given-names>TD</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Jaffe</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Madden</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Effective clearance of methotrexate using high-flux hemodialysis
membranes</article-title>
          <source>Am J Kidney Dis</source>
          <year>1996</year>
          <volume>28</volume>
          <fpage>846</fpage>
          <lpage>854</lpage>
          <pub-id pub-id-type="pmid">8957036</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salaffi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Manganelli</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carotti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Subiaco</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lamanna</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cervini</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Methotrexate-induced pneumonitis in patients with rheumatoid arthritis
and psoriatic arthritis: report of five cases and review of the
literature</article-title>
          <source>Clin Rheumatol</source>
          <year>1997</year>
          <volume>16</volume>
          <fpage>296</fpage>
          <lpage>304</lpage>
          <pub-id pub-id-type="pmid">9184269</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Kuo</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Guh</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>HC</given-names>
            </name>
          </person-group>
          <article-title>Pancytopenia after low dose methotrexate therapy in a hemodialysis
patient: case report and review of literature</article-title>
          <source>Ren Fail</source>
          <year>2006</year>
          <volume>28</volume>
          <fpage>95</fpage>
          <lpage>97</lpage>
          <pub-id pub-id-type="pmid">16526326</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Toffoli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Innocenti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Corona</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tumolo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sartor</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effect of methylenetetrahydrofolate reductase 677C--&gt;T polymorphism
on toxicity and homocysteine plasma level after chronic methotrexate treatment of
ovarian cancer patients</article-title>
          <source>Int J Cancer</source>
          <year>2003</year>
          <volume>103</volume>
          <fpage>294</fpage>
          <lpage>299</lpage>
          <pub-id pub-id-type="pmid">12471611</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
